Topical ketoconazole: a systematic review of current dermatological applications and future developments

Abstract

Introduction: Although labeling changes and market withdrawal have been implemented for oral ketoconazole (KTZ) due to serious adverse effects (AEs), topical KTZ is generally thought to be effective and safe for the treatment of superficial fungal infections. New dermatologic indications for the use of topical KTZ have arisen such as onychomycosis, blepharitis, and hair loss. This article aims to review the literature on topical KTZ’s efficacy and AEs, as well as provide an overview on current insights regarding its mechanism of action and upcoming developments.

Methods: A PubMed search was done to include randomized controlled trials (RCTs) focusing on the use of topical KTZ in human subjects.

Results: Forty studies with 4566 patients were included in this review. Topical KTZ is clinically effective for the treatment of Malassezia-related conditions such as seborrheic dermatitis (SD) and pityriasis versicolor (PV) with a reported efficacy of 63–90% and 71–89%, respectively.

Conclusions: Topical KTZ demonstrates high clinical efficacy for Malassezia-related conditions. More efficacious alternatives are now available for Tinea and Candida. Although topical KTZ is safe, clinicians should be aware that allergic contact dermatitis may occur. Further studies should be completed to investigate the use of topical KTZ for hair loss and inflammatory dermatoses.

Keywords:

• Topical ketoconazole
• seborrheic dermatitis
• pityriasis versicolor
• androgenetic alopecia

Acknowledgments

The authors would like to thank the University of California Irvine Clinical Dermatology Research Center for their continuous support and the United States Food and Drug Administration for providing safety and adverse effects information on topical ketoconazole.

Disclosure statement

The authors have no conflicts of interest to disclose.